CC-99712

· Celgene

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CC-99712, covering 2024-08-30 to 2024-08-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]

See pricing